Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 101 - 150 out of 23,111

Document Document Title
WO/2017/094743A1
An agent for the treatment and/or prevention of conditions associated with hyperglucocorticoidemia, characterized in containing as an active ingredient a compound indicated by formula (I): (where ring A is (II), ring B is a substituted o...  
WO/2017/085190A1
A composition comprising one or more polyphenols, such as oleuropein, rutin, curcumin or quercetin, can treat or prevent sarcopenia, reduce a loss of muscle functionality (e.g. muscle strength, gait speed, etc.), increase muscle function...  
WO/2017/085138A1
A composition comprising whey protein and optionally Vitamin D and calcium can be administered to an individual to decrease fat deposition in muscle; increase muscle density; improve or maintain muscle quality; and/or treat or prevent mu...  
WO/2017/082288A1
A compound represented by any one of formulae (I) to (XXII), or a pharmaceutically acceptable salt thereof.  
WO/2017/081111A1
The present invention provides compounds of formula (I) (I) wherein A, R1, R2 and R3 are as described herein, as well as pharmaceutically acceptable salts thereof for use in the treatment, prevention and/or delay of progression of amyotr...  
WO/2017/083776A1
The invention provides for AAV vectors expressing the ANO5 gene and antioxidant therapy as methods of inducing muscle regeneration and a method of treating muscular dystrophy.  
WO/2017/077516A2
The invention relates to compounds for use in the treatment of telomere related diseases and/or telomere related medical conditions, particularly wherein said telomere related diseases and/or telomere related medical conditions are cance...  
WO/2017/079195A1
Provided herein are compounds of Formula (I): or a pharmaceutically acceptable salt thereof, and compositions comprising such compounds that are useful for increasing the amount of NAD+ in cells. Also disclosed are methods of using the d...  
WO/2017/077516A3
The invention relates to compounds for use in the treatment of telomere related diseases and/or telomere related medical conditions, particularly wherein said telomere related diseases and/or telomere related medical conditions are cance...  
WO/2017/072984A1
The present invention addresses the problem of providing a novel therapeutic agent and treatment method for amyotrophic disorders, more specifically, a therapeutic agent and treatment method for neurogenic atrophy disorders such as amyot...  
WO/2017/069270A1
Provided is a novel compound or a pharmaceutically acceptable salt thereof that is useful for treating or preventing, on the basis of the PAM effects of the GABAB receptor, diseases such as autism spectrum disorder, fragile X syndrome, s...  
WO/2017/065077A1
The purpose of the present invention is to provide a safe muscle-enhancing agent capable of effectively increasing or maintaining muscle mass and muscle strength, and suppressing a decrease in muscle mass and muscle strength. Further pro...  
WO/2017/064193A1
The invention relates to the uses of an SGLT-2 inhibitor, for example improving the health of a subject or treating metabolic myopathies.  
WO/2017/061614A1
The present invention relates to: a calpain activation inhibitor, a muscle damage inhibitor, a muscular endurance improver or a muscle fatigue recovery agent containing, as an active ingredient, an ω-methylsulfinylalkyl isothiocyanate o...  
WO/2017/062468A8
Provided herein are compounds I, II or III and compositions useful in increasing PPAR8 activity. The compounds and compositions provided herein are useful for the treatment of PPAR8 related diseases (e.g., muscular diseases, vascular dis...  
WO/2017/059554A1
The present invention relates to a method and use of the AAV-XBP1S/GFP virus in the prevention and treatment of amyotrophic lateral sclerosis, as presented in the in vivo studies in figure 6/9.  
WO/2017/062468A1
Provided herein are compounds and compositions useful in increasing PPAR8 activity. The compounds and compositions provided herein are useful for the treatment of PPAR8 related diseases (e.g., muscular diseases, vascular disease, demyeli...  
WO/2017/060750A1
The invention relates to the use of a composition from a plant extract of Withania somnifera, to treat or limit development of pathologies of the myelin, including multiple sclerosis disease.  
WO/2017/057562A1
The present invention provides a therapeutic agent and/or a prophylactic agent and the like for a peripheral nerve disorder or a spinal injury having zonisamide or an alkali metal salt thereof as an active ingredient.  
WO/2017/054086A1
A method of treating myopathy in a mammal is provided. The method includes administering to the mammal exosomes genetically modified to incorporate a muscle protein useful to treat the myopathy or nucleic acid encoding the protein.  
WO/2017/059309A1
Compositions and methods of treating a subject with an acute traumatic injury are disclosed. The methods include administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising a potassium chann...  
WO/2017/050259A1
Provided are prodrugs of gamma-hydroxybutyric acid as well as compositions and uses thereof.  
WO/2017/049411A1
Disclosed herein are methods and compositions for increasing and decreasing the permeability of the blood brain barrier for the treatment of diseases and conditions and to facilitate the delivery of agents to the brain, as well as method...  
WO/2017/047769A1
In the present invention, a compound selected from cyclobakuchiol A, cyclobakuchiol B and derivatives thereof, a pharmacologically acceptable salt thereof or a prodrug thereof, is a low molecular weight compound having an action of selec...  
WO/2017/047741A1
A novel antisense nucleic acid and the like inhibiting myostatin at an mRNA level have been required. Provided is a definite antisense oligomer that enables skipping of the second exon of myostatin gene and induces degradation of mRNA of...  
WO/2017/047707A1
The present invention provides an oligomer that enables skipping of exon 45 in the human dystrophin gene.  
WO/2017/043466A1
[Problem] To provide an anti-EphA4 antibody or an EphA4-binding fragment thereof that is capable of binding to EphA4 and inhibiting the binding of EphA4 and the ligands thereof, and a pharmaceutical composition containing these as an act...  
WO/2017/042196A3
The present invention relates to agents that prevent or reverse process of stem cell senescence. Further, the invention relates to methods and compositions useful in the prevention and/or treatment of stem senescence.  
WO/2017/043630A1
The present invention provides a therapeutic agent for sarcopenia or metabolic diseases, which contains a mu-crystalline (CRYM)-inhibiting substance as an active ingredient. The inhibiting substance is selected from the group consisting ...  
WO/2017/042198A3
Abstract of the invention: The present invention relates to agents that induce mitochondrial unfolded protein response (UPR mt ) in muscle stem cells and prevents or reverse process of muscle stem cell senescence. Further, the invention ...  
WO/2017/042318A1
The present invention relates to methods and pharmaceutical compositions for the treatment of cancer-induced cachexia. In particular, the present invention relates to a method of treating cancer-induced cachexia in a subject in need ther...  
WO/2017/036852A1
The present invention relates to novel means for regulating dystrophin expression for treating diseases in a subject, and more particularly to novel means for regulating dystrophin expression for treating dystrophin associated diseases v...  
WO/2017/037719A1
Novel aminoglycosides, represented by Formulae la and lb, as defined in the instant specification, designed to exhibit stop codon mutation readthrough activity, are provided. Also provided are pharmaceutical compositions containing the s...  
WO/2017/037718A1
Novel pseudo-trisaccharide aminoglycosides, represented by Formula I, as defined in the instant specification, designed to exhibit stop codon mutation readthrough activity, are provided. Also provided are pharmaceutical compositions cont...  
WO/2017/038925A1
The present invention addresses the problem of providing a pharmaceutical composition that has a high safety and with which the long-term stability can be ensured and the reduction in the amount of an active ingredient accompanying the o...  
WO/2017/036992A1
The invention provides compositions comprising a medium chain triglyceride and a urolithin. The invention also provides uses and methods associated with, or making use of the compositions,such as a medicament, dietary supplement, functio...  
WO/2017/038991A1
Provided are a composition for muscle building and a method for building muscle. The present invention pertains to a composition for muscle building, said composition comprising citrulline or a salt thereof and a branched amino acid or a...  
WO/2017/035659A1
In one aspect, the Invention relates to methods and compositions to remove replicate genetic material, such as duplicate copy number variations (CNVs) present in genetic material using targeted endonuclease technology with one guide, suc...  
WO/2017/038945A1
Provided is a therapeutic agent for diseases associated with the accumulation of abnormal substances in cells which contains, as an active ingredient, a substance for suppressing the expression of ERdj8, or a substance for suppressing an...  
WO/2017/037567A1
This invention relates to a method of treating a condition or a disease associated with decreased levels or activity of frataxin, including Friedreich's ataxia, comprising administering to a subject in needthereof a therapeutically effec...  
WO/2017/037717A1
Novel pseudo-disaccharide and pseudo-trisaccharide aminoglycosides, represented by Formulae I or Ia, as defined in the instant specification, designed to exhibit stop codon mutation readthrough activity, are provided. Also provided are p...  
WO/2017/036993A1
The invention provides compositions comprising a source of protein and a urolithin. The invention also provides uses and methods associated with, or making use of the compositions, such as a medicament, dietary supplement, functional foo...  
WO/2017/033963A1
The present invention addresses the problem of providing a substance that has an effect of increasing ATP in cells, in particular, an ATP increasing agent that has an effect much stronger than the increasing effect achieved by using inos...  
WO/2017/027967A1
The present application relates to a-substituted amino acid compounds of the Formula (I), compositions comprising these compounds and their use, in particular for the treatment of diseases, disorders or conditions characterized by or ass...  
WO/2017/031502A1
The present invention relates to methods for conferring mTOR mediated physiological benefits by administering a composition having phospholipids, omega-3 fatty acids, and an antioxidant, or a krill extract to a mammal in need thereof.  
WO/2017/026429A1
The present invention pertains to a muscle synthesis promoting agent which exhibits muscle synthesis promotion effects in a level equal to or higher than whey protein but with a lesser ingestion (administration) amount than whey protein....  
WO/2017/026516A1
The present invention provides a compound represented by formula (I) or a pharmaceutically acceptable salt thereof or a solvate of these. The present invention provides a compound having Nrf2 activation ability.  
WO/2017/014120A1
Provided are a composition for stimulating TRPV1, a use for the composition for stimulating TRPV1, and a method for stimulating TRPV1. It was discovered that a specific cyclic dipeptide or a salt thereof has a TRPV1 stimulation effect. T...  
WO/2017/013031A1
The present invention relates to the field of muscle regeneration, and more particularly to the replenishment of the in vivo muscle stem cells pool. It more specifically relates to a 5- hydroxytryptamine B1 receptor-stimulating agent, an...  
WO/2017/009491A1
A natural glucose transport promoting peptide comprising a glucose transport promoting fragment of a protein selected from SEQUENCE ID NO's: 1 to 6, and a composition comprising a plurality of glucose transport promoting peptides, is des...  

Matches 101 - 150 out of 23,111